ArticleBMC nephrology2026

Empagliflozin versus dapagliflozin for kidney outcomes in stage 3 chronic kidney disease: a propensity score-matched multi-center cohort study.

Joyita Bharati et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.